Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC in Platinum-Resistant Recurrent Ovarian Cancer
NCT03220932Phase 3Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cisplatin in ovarian epithelial cancer, sponsored by Hospices Civils de Lyon. Status: unknown.
02
Drugs
cisplatin
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT03220932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220932.